A non-interventional study among cardiology patients - this is a new field of cooperation between the Biostat Research and Development Center and the pharmaceutical and biotechnology company Adamed Pharma.

Biostat and Adamed Pharma have just signed an agreement for a non-interventional study among cardiology patients.

In the study, we will compare the efficacy and safety of triple therapy compared to dual therapy

 –  explains Edyta Klemba  –  Pharma Division Director at Biostat's Research and Development Center.

As part of the concluded agreement, Biostat's side will be the full operation of the study, including, among others: selection and contracting of centers, providing eCRF tools, and data management, preparing documentation for the study, obtaining approval from the Bioethics Committee, monitoring and project management.

We are pleased that our competencies and many years of experience in handling non-interventional studies have once again been recognized by such a serious partner as Adamed Pharma

 – adds Rafal Piszczek  –  CEO of Biostat.

> Biostat. Full-service CRO